J 2020

Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration

ARDAN, Taras, Monika BAXA, Božena LEVINSKÁ, Miroslava SEDLÁČKOVÁ, The Duong NGUYEN et. al.

Základní údaje

Originální název

Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration

Autoři

ARDAN, Taras (203 Česká republika), Monika BAXA (203 Česká republika), Božena LEVINSKÁ (203 Česká republika), Miroslava SEDLÁČKOVÁ (203 Česká republika, domácí), The Duong NGUYEN (203 Česká republika), Jiří KLÍMA (203 Česká republika), Štefan JUHÁS (203 Česká republika), Jana JUHÁSOVÁ (203 Česká republika), Petra ŠMATLÍKOVÁ (203 Česká republika), Petra VOCHOZKOVÁ (203 Česká republika), Jan MOTLÍK (203 Česká republika) a Zdenka ELLEDEROVÁ (203 Česká republika, garant)

Vydání

Disease models & mechanisms, Cambridge, Company of Biologists Ltd. 2020, 1754-8403

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10601 Cell biology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.758

Kód RIV

RIV/00216224:14110/20:00115361

Organizační jednotka

Lékařská fakulta

UT WoS

000518475500008

Klíčová slova anglicky

Large animal model; TgHD; Brain; Huntingtin; Neuropathology

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 15. 7. 2020 10:26, Mgr. Tereza Miškechová

Anotace

V originále

Recently developed therapeutic approaches for the treatment of Huntington’s disease (HD) require preclinical testing in large animal models. The minipig is a suitable experimental animal because of its large gyrencephalic brain, body weight of 70-100 kg, long lifespan, and anatomical, physiological and metabolic resemblance to humans. The Libechov transgenic minipig model for HD (TgHD) has proven useful for proof of concept of developing new therapies. However, to evaluate the efficacy of different therapies on disease progression, a broader phenotypic characterization of the TgHD minipig is needed. In this study, we analyzed the brain tissues of TgHD minipigs at the age of 48 and 60-70 months, and compared them to wild-type animals. We were able to demonstrate not only an accumulation of different forms of mutant huntingtin (mHTT) in TgHD brain, but also pathological changes associated with cellular damage caused by mHTT. At 48 months, we detected pathological changes that included the demyelination of brain white matter, loss of function of striatal neurons in the putamen and activation of microglia. At 60-70 months, we found a clear marker of neurodegeneration: significant cell loss detected in the caudate nucleus, putamen and cortex. This was accompanied by clusters of structures accumulating in the neurites of some neurons, a sign of their degeneration that is also seen in Alzheimer’s disease, and a significant activation of astrocytes. In summary, our data demonstrate age-dependent neuropathology with later onset of neurodegeneration in TgHD minipigs.